Exciting New Therapies for Advanced Melanoma
New clinical trials data presented at ASCO 2011 revealed a striking response to drugs ipilimumab (recently-approved), and vemurafenib, a new drug for patients with the most common subtype of advanced melanoma (B-RAF V600E Mutation). Dr. Kim Margolin, a Melanoma specialist at the Fred Hutchinson Cancer Research Institute in Seattle helped us understand why this new drug is making news and why patients have reason to be hopeful.
Experts & Guests
Kim Margolin, M.D.
Professor, University of Washington, Seattle Cancer Care AllianceDr. Margolin’s clinical efforts are in the treatment of melanoma, kidney cancer and germ cell cancer, and she is particularly interested in clinical trials that provide the newest investigational therapies for her patients. Melanoma and kidney cancer are often treated with immunotherapy, including vaccines, cytokines and immune-cell infusions. Germ cell cancer can be treated effectively with high-dose chemotherapy and autologous... more >